The estimated Net Worth of Eric Thomas Schmidt is at least $6.83 Million dollars as of 15 March 2022. Mr. Schmidt owns over 11,469 units of Allogene Therapeutics Inc stock worth over $292,589 and over the last 6 years he sold ALLO stock worth over $3,078,553. In addition, he makes $3,460,070 as Chief Financial Officer at Allogene Therapeutics Inc.
Sign up
Mr. Schmidt ALLO stock SEC Form 4 insiders trading
Eric has made over 8 trades of the Allogene Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 11,469 units of ALLO stock worth $87,508 on 15 March 2022.
The largest trade he's ever made was selling 30,000 units of Allogene Therapeutics Inc stock on 14 January 2021 worth over $945,600. On average, Eric trades about 4,595 units every 29 days since 2019. As of 15 March 2022 he still owns at least 100,546 units of Allogene Therapeutics Inc stock.
You can see the complete history of Mr. Schmidt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Schmidt biography
Eric T. Schmidt Ph.D. serves as Chief Financial Officer of the Company. Prior to joining us, Dr. Schmidt was a Managing Director and Senior Research Analyst at Cowen and Company, LLC. He joined Cowen as a Research Analyst in 1998 where he covered biotechnology stocks until June 2018. He was previously a Vice President and Research Analyst for UBS Securities. He has also served on the board of directors for Relmada Therapeutics, Inc. since December 2019. Dr. Schmidt obtained a Bachelor of Arts in Chemistry from the University of Pennsylvania and a Ph.D. in Biology from the Massachusetts Institute of Technology, where he serves on the Visiting Committee for the Department of Biology.
What is the salary of Eric Schmidt?
As the Chief Financial Officer of Allogene Therapeutics Inc, the total compensation of Eric Schmidt at Allogene Therapeutics Inc is $3,460,070. There are 3 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
How old is Eric Schmidt?
Eric Schmidt is 51, he's been the Chief Financial Officer of Allogene Therapeutics Inc since 2018. There are 13 older and 7 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
What's Eric Schmidt's mailing address?
Eric's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DR, REDWOOD CITY, CA, 94063.
Insiders trading at Allogene Therapeutics Inc
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun und Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
What does Allogene Therapeutics Inc do?
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
What does Allogene Therapeutics Inc's logo look like?
Complete history of Mr. Schmidt stock trades at Allogene Therapeutics Inc, Relmada Therapeutics Inc und Revolution Medicines Inc
Allogene Therapeutics Inc executives and stock owners
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Chang,
President, Chief Executive Officer, Co-Founder, Director -
Rafael Amado,
Executive Vice President - Research and Development, Chief Medical Officer -
Arie Belldegrun,
Executive Chairman of the Board -
Eric Schmidt,
Chief Financial Officer -
Alison Moore,
Chief Technical Officer -
Dr. David D. Chang M.D., Ph.D.,
Co-Founder, Pres, CEO & Director -
Joshua Kazam,
Co-Founder, Director -
Dr. Rafael G. Amado M.D.,
Exec. VP of R&D -
Dr. Arie S. Belldegrun F.A.C.S., FACS, M.D.,
Co-Founder & Exec. Chairman -
Dr. Arie S. Belldegrun F.A.C.S., M.D., FACS,
Co-Founder & Exec. Chairman -
Dr. Rafael G. Amado,
Chief Medical Officer and Exec. VP of R&D -
Dr. Alison Moore Ph.D.,
Chief Technical Officer -
Dr. Eric Thomas Schmidt Ph.D.,
Chief Financial Officer -
Veer Bhavnagri,
Gen. Counsel & Compliance Officer -
Franz Humer,
Independent Director -
Deborah Messemer,
Independent Director -
Owen Witte,
Independent Director -
Joshua A. Kazam,
Co-Founder & Director -
Veer Bhavnagri,
Chief Compliance Officer, General Counsel -
Todd Sisitsky,
Independent Director -
John DeYoung,
Independent Director -
David Bonderman,
Lead Independent Director -
Stephen Cheng,
Chief Information Officer -
David M. Tanen J.D.,
Sec. -
Christine Cassiano,
Chief Communications Officer -
Barbra Sasu,
Chief Scientific Officer -
Timothy L. Moore,
Chief Technical Officer -
Yinlin Jack Chen,
SVP, Finance -
Inc Pfizer,
10% owner -
Earl Martin Douglas,
SVP, General Counsel -
Elizabeth A. Barrett,
-
Vicki L Sato,
-
Equity Holdings 2 B.V. Pf,
10% owner -
Stephen Mayo,
-
Zachary Roberts,
EVP of R&D -
Lillian Smith,
VP, Corporate Counsel -
Geoffrey M. Parker,
CHIEF FINANCIAL OFFICER